A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
Abstract PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Speci...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/406462c44b26424ba7040c4796c0ef2d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:406462c44b26424ba7040c4796c0ef2d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:406462c44b26424ba7040c4796c0ef2d2021-12-02T16:04:29ZA subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures10.1038/s41698-021-00199-82397-768Xhttps://doaj.org/article/406462c44b26424ba7040c4796c0ef2d2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00199-8https://doaj.org/toc/2397-768XAbstract PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA aberration profiles (mutational signatures) are induced by homologous recombination deficiency (HRD) and their presence can be used to assess the presence or absence of HR deficiency in a given tumor biopsy even in the absence of an observed alteration of an HR gene. We derived various HRD-associated mutational signatures from whole-genome and whole-exome sequencing data in the lung adenocarcinoma and lung squamous carcinoma cases from TCGA, and in a patient of ours with stage IVA lung cancer with exceptionally good response to platinum-based therapy, and in lung cancer cell lines. We found that a subset of the investigated cases, both with and without biallelic loss of BRCA1 or BRCA2, showed robust signs of HR deficiency. The extreme platinum responder case also showed a robust HRD-associated genomic mutational profile. HRD-associated mutational signatures were also associated with PARP inhibitor sensitivity in lung cancer cell lines. Consequently, lung cancer cases with HRD, as identified by diagnostic mutational signatures, may benefit from PARP inhibitor therapy.Miklos DiossyZsofia SztupinszkiJudit BorcsokMarcin KrzystanekViktoria TiszaSandor SpisakOrsolya RuszJozsef TimarIstván CsabaiJanos FillingerJudit MoldvayAnders Gorm PedersenDavid SzutsZoltan SzallasiNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Miklos Diossy Zsofia Sztupinszki Judit Borcsok Marcin Krzystanek Viktoria Tisza Sandor Spisak Orsolya Rusz Jozsef Timar István Csabai Janos Fillinger Judit Moldvay Anders Gorm Pedersen David Szuts Zoltan Szallasi A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| description |
Abstract PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA aberration profiles (mutational signatures) are induced by homologous recombination deficiency (HRD) and their presence can be used to assess the presence or absence of HR deficiency in a given tumor biopsy even in the absence of an observed alteration of an HR gene. We derived various HRD-associated mutational signatures from whole-genome and whole-exome sequencing data in the lung adenocarcinoma and lung squamous carcinoma cases from TCGA, and in a patient of ours with stage IVA lung cancer with exceptionally good response to platinum-based therapy, and in lung cancer cell lines. We found that a subset of the investigated cases, both with and without biallelic loss of BRCA1 or BRCA2, showed robust signs of HR deficiency. The extreme platinum responder case also showed a robust HRD-associated genomic mutational profile. HRD-associated mutational signatures were also associated with PARP inhibitor sensitivity in lung cancer cell lines. Consequently, lung cancer cases with HRD, as identified by diagnostic mutational signatures, may benefit from PARP inhibitor therapy. |
| format |
article |
| author |
Miklos Diossy Zsofia Sztupinszki Judit Borcsok Marcin Krzystanek Viktoria Tisza Sandor Spisak Orsolya Rusz Jozsef Timar István Csabai Janos Fillinger Judit Moldvay Anders Gorm Pedersen David Szuts Zoltan Szallasi |
| author_facet |
Miklos Diossy Zsofia Sztupinszki Judit Borcsok Marcin Krzystanek Viktoria Tisza Sandor Spisak Orsolya Rusz Jozsef Timar István Csabai Janos Fillinger Judit Moldvay Anders Gorm Pedersen David Szuts Zoltan Szallasi |
| author_sort |
Miklos Diossy |
| title |
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| title_short |
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| title_full |
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| title_fullStr |
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| title_full_unstemmed |
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| title_sort |
subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/406462c44b26424ba7040c4796c0ef2d |
| work_keys_str_mv |
AT miklosdiossy asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT zsofiasztupinszki asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT juditborcsok asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT marcinkrzystanek asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT viktoriatisza asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT sandorspisak asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT orsolyarusz asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT jozseftimar asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT istvancsabai asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT janosfillinger asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT juditmoldvay asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT andersgormpedersen asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT davidszuts asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT zoltanszallasi asubsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT miklosdiossy subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT zsofiasztupinszki subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT juditborcsok subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT marcinkrzystanek subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT viktoriatisza subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT sandorspisak subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT orsolyarusz subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT jozseftimar subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT istvancsabai subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT janosfillinger subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT juditmoldvay subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT andersgormpedersen subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT davidszuts subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures AT zoltanszallasi subsetoflungcancercasesshowsrobustsignsofhomologousrecombinationdeficiencyassociatedgenomicmutationalsignatures |
| _version_ |
1718385201805000704 |